Business
Branded Legacy, Inc. Announces Provisional Patent Filing by BioLegacy for Disruptive Air-Driven Intranasal Platform Targeting Multi-Billion-Dollar Global Therapeutics Market
Branded Legacy, Inc. Announces Provisional Patent Filing by BioLegacy for Disruptive Air-Driven Intranasal Platform Targeting Multi-Billion-Dollar Global Therapeutics Market.
About this update from Branded Legacy Inc.
[{"type":"text","content":"\r\n\r\n \r\n \r\n Branded Legacy, Inc. Announces Provisional Patent Filing by BioLegacy for Disruptive Air-Driven Intranasal Platform Targeting Multi-Billion-Dollar Global Therapeutics Market\r\n \r\n \r\n\r\n\r\nBranded Legacy, Inc. Announces Provisional Patent Filing by BioLegacy for Disruptive Air-Driven Intranasal Platform Targeting Multi-Billion-Dollar Global Therapeutics Market\r\nRevolutionary platform aims to make life-saving overdose reversal therapies more affordable, accessible, and effective worldwide\r\n\r\n\r\n\r\n\r\n\r\nVANCOUVER, British Columbia, Sept. 30, 2025 (GLOBE NEWSWIRE) -- via IBN -- Branded Legacy, Inc. (OTC: BLEG), a dynamic holding company focused on innovative life sciences and wellness solutions, is thrilled to announce that its subsidiary, BioLegacy Evaluative Group Inc. (\"BioLegacy\"), has filed a provisional patent application with the United States Patent and Trademark Office (USPTO) for its groundbreaking intranasal drug delivery platform titled \"Air-Driven Unitary Intranasal Drug Delivery Device for Stable and Reconstitutable Medicaments.\" This cutting-edge technology marks a significant leap forward in nasal drug administration, tackling key challenges in emergency and self-administered pharmaceuticals. The compact, ergonomic, and air-powered device delivers precise, reliable, and cost-effective intranasal dosing for both stable liquid formulations—like naloxone for opioid overdose reversal—and lyophilized or unstable drugs that require on-demand reconstitution. Key Innovations Driving the Platform: \r\n Air-Driven Precision Delivery – A compressible air chamber drives medication through a precision atomizer, ensuring complete and consistent dosing with minimal residual volume.\r\n Dual-Function Architecture – Accommodates both pre-formed stable solutions and unstable powder-based medicaments that are reconstituted seconds before use.\r\n Unitary Blow-Fill-Seal Construction – Manufactured as a single, sterile component minimizing contamination risk, assembly steps, and production cost.\r\n Sequential Frangible Membranes – Engineered rupture zones enable user-activated mixing and delivery through a simple one- or two-step squeeze mechanism.\r\n Ergonomic, Portable Design – Thumb-sized, single-use format ensures easy...